Future Virology最新文献

{"title":"Blood types (ABO/Rhesus) and SARS-CoV-2 infection: a retrospective, cross-sectional study in 2828 healthcare workers.","authors":"Betul Copur,&nbsp;Serkan Surme,&nbsp;Ugurcan Sayili,&nbsp;Gulsah Tuncer,&nbsp;Melike Nur Ozcelik,&nbsp;Hulya Yilmaz-Ak,&nbsp;Muge Topal,&nbsp;Sumeyye Ustun-Al,&nbsp;Filiz Pehlivanoglu,&nbsp;Gonul Sengoz","doi":"10.2217/fvl-2022-0128","DOIUrl":"https://doi.org/10.2217/fvl-2022-0128","url":null,"abstract":"<p><p><b>Background:</b> The authors aimed to investigate the relationship between ABO/Rhesus blood types and the risk of SARS-CoV-2 infection and hospitalization in healthcare workers (HCWs). <b>Materials & methods:</b> This study compared HCWs with (n = 510) and without (n = 2318) SARS-CoV-2 infection. Risk factors for SARS-CoV-2 infection and hospitalization in HCWs were shown as odds ratios with 95% CI. <b>Results:</b> Blood group O was found to be protective by 20% from the risk of developing SARS-CoV-2 infection in HCWs (29.2 vs 33.8%; odds ratio: 0.808; 95% CI: 0.655-0.996; p = 0.045). The prevalence of group O was lower in hospitalized patients than in outpatients (25 vs 29.5%; p = 0.614). <b>Conclusion:</b> These findings suggest that blood groups are associated with the development of SARS-CoV-2 infection.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40650724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variation analysis of SARS-CoV-2 complete sequences from Iran.","authors":"Jale Moradi,&nbsp;Parnia Moradi,&nbsp;Amir H Alvandi,&nbsp;Ramin Abiri,&nbsp;Mohsen Moghoofei","doi":"10.2217/fvl-2021-0056","DOIUrl":"https://doi.org/10.2217/fvl-2021-0056","url":null,"abstract":"<p><p><b>Aim:</b> SARS-CoV-2 is an emerging coronavirus that was discovered in China and rapidly spread throughout the world. The authors looked at nucleotide and amino acid variations in SARS-CoV-2 genomes, as well as phylogenetic and evolutionary events in viral genomes, in Iran. <b>Materials & methods:</b> All SARS-CoV-2 sequences that were publicly released between the start of the pandemic and 15 October 2021 were included. <b>Results:</b> The majority of mutations were found in vaccine target proteins, Spike and Nucleocapsid proteins, and nonstructural proteins. The majority of the viruses that circulated in the early stages of the pandemic belonged to the B.4 lineage. <b>Conclusion:</b> We discovered the prevalence of viral populations in Iran. As a result, tracking the virus's variation in Iran and comparing it with a variety of nearby neighborhoods may reveal a pattern for future variant introductions.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40437541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ion channels and ions as therapeutic targets and strategies for herpes simplex virus infection","authors":"Binhua Luo, Liqiong Ding","doi":"10.2217/fvl-2022-0052","DOIUrl":"https://doi.org/10.2217/fvl-2022-0052","url":null,"abstract":"Herpes simplex virus (HSV) is a highly contagious virus that cannot be completely cured currently. Existing treatment methods are mainly nucleoside antiviral drugs, and the emergence of drug-resistant strains severely limits their use. There is an urgent need to discover antiviral drugs that act on new targets. Ion channels, a class of cellular proteins with a wide range of functions, have become critical host factors for a wide variety of viral infections. Ion channel blockers have been shown to have antiviral activity. In this study, we discuss the role of ion channels and ions in the HSV life cycle, and the potential of targeting ion channels as a novel, pharmacologically safe and wide-range antiviral treatment option.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43226247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A plain language summary of the Janssen COVID-19 vaccine effectiveness and safety as a single dose and with a booster","authors":"F. Struyf, J. Sadoff, K. Hardt, M. Douoguih","doi":"10.2217/fvl-2022-0105","DOIUrl":"https://doi.org/10.2217/fvl-2022-0105","url":null,"abstract":"Summary This is a summary of the results of 2 global clinical studies of the Janssen Ad26.COV2.S vaccine against COVID-19. The ENSEMBLE study looked at the effectiveness of a single injection of the vaccine. The separate ENSEMBLE2 study looked at the effectiveness of a booster dose of the vaccine given 2 months after the first dose. In both studies, people received either the vaccine or a placebo. Vaccine effectiveness was evaluated 14 and 28 days after vaccination to allow sufficient time for generation of an immune response. In ENSEMBLE, compared to the placebo, a single dose of the vaccine prevented: 56% of moderate to severe-critical COVID-19 cases occurring at least 14 days after vaccination 53% of moderate to severe-critical COVID-19 cases occurring at least 28 days after vaccination 75% of severe-critical COVID-19 cases occurring at least 28 days after vaccination 76% of people with COVID-19 from needing to be hospitalized for treatment 83% of COVID-19–related deaths The vaccine continued to work well for at least 6 months after a single vaccine injection. In ENSEMBLE2, compared to the placebo, a single dose of the vaccine followed by a booster dose 2 months later prevented: 75% of moderate to severe-critical COVID-19 cases occurring at least 14 days after booster vaccination 100% of severe-critical COVID-19 cases occurring at least 14 days after booster vaccination In ENSEMBLE2, there were too few cases of COVID-19 to estimate vaccine effectiveness for preventing COVID-19–related deaths or hospitalization. ENSEMBLE2 was done during early 2021, when several COVID-19 vaccines became available by emergency use authorization. For ethical reasons, people could check whether they had received vaccine or placebo and decide whether they could be vaccinated outside of the study. This meant that the researchers could not look at the long-term effectiveness of the vaccine. In both studies, after receiving the vaccine, some people experienced pain at the injection site, headache, tiredness, muscle pain, and nausea. In most cases, these were mild and went away within a few days. Serious side effects were very rare. In ENSEMBLE, blood clots, seizures, hives, and ringing in the ears were more common in the people who got the vaccine than in those who got the placebo. These side effects were very rare. In ENSEMBLE2, bleeding, hives, and ringing in the ears were slightly more common in people who got the vaccine than those who got the placebo. In ENSEMBLE2, blood clots were more common in people who got the placebo. At the time of the study, it was not clear if these side effects were caused by the vaccine. The vaccine was effective at protecting against moderate to severe-critical COVID-19 at 14 days after a single injection. Effectiveness was increased by a booster injection given 2 months after the first injection. You can find more detailed information and references in the original articles. Links to these articles can be found at the end of this sum","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42304045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of cycle threshold values in mass screening by reverse-transcription-PCR during COVID-19 pandemic in Belgium: a decision-making support?","authors":"Patrice Dufour,&nbsp;Henry Paridaens,&nbsp;Jean-Marc Senterre,&nbsp;Jean-Marc Minon","doi":"10.2217/fvl-2022-0020","DOIUrl":"https://doi.org/10.2217/fvl-2022-0020","url":null,"abstract":"<p><p><b>Aim:</b> The Belgium's strategy against COVID-19 was partly based on mass screening. Here, we reported the results observed in a Belgian mass screening center. <b>Materials & methods:</b> Between October 2020 and February 2021, 32,089 samples were collected analyzed with reverse-transcription PCR (Thermo Fisher Scientific kits and apparatus). Patients were categorized according to their contagiousness (extrapolated from the cycle threshold [Ct] values and the recommendation of Sciensano). <b>Results:</b> We observed association between Ct values and age, with higher Ct observed in extreme age groups (<6 years and >75 years). <b>Conclusion:</b> The analysis of the evolution of the contagiousness of these patients tested twice within a 7-day period showed the relevancy of the recommendation edited by Sciensano.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40381552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Similarity between cutaneous reactions due to SARS-CoV-2 and its vaccinations.","authors":"Ömer Kutlu,&nbsp;Selami Aykut Temiz","doi":"10.2217/fvl-2021-0357","DOIUrl":"https://doi.org/10.2217/fvl-2021-0357","url":null,"abstract":"the common","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reinfection and reactivation of SARS-CoV-2.","authors":"Razieh Dowran,&nbsp;Amirmasoud Rayati Damavandi,&nbsp;Talat Mokhtari Azad","doi":"10.2217/fvl-2021-0212","DOIUrl":"https://doi.org/10.2217/fvl-2021-0212","url":null,"abstract":"<p><p>As the cases of SARS-CoV-2 infection escalates, the essence of in-depth knowledge around acquired immunity and emergence of reinfection and reactivation have to be captured. While being a rare phenomenon, reinfection occurs as the result of diminishing protection conferred by antibodies, especially IgG. Reactivation is more concerned with the role of various elements including shedding lingering viral RNA for a prolonged time and incomplete resolution of infection along with the insight of dormant viral exosomes' role. The concept of testing positive after two consecutive negative results requires proper discrimination of reinfection from reactivation. In this review, we summarized the current evidence for possible mechanisms leading to viral reactivation or test re-positivity. We also pointed out risk factors associated with both reinfection and reactivation.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40384255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid antigen test for SARS-CoV-2: results of validation and use in real life.","authors":"Irena Grmek Kosnik,&nbsp;Urska Dermota,&nbsp;Andrej Golle,&nbsp;Tjasa Zohar Cretnik","doi":"10.2217/fvl-2022-0045","DOIUrl":"https://doi.org/10.2217/fvl-2022-0045","url":null,"abstract":"<p><p><b>Aim:</b> To verify a SARS-CoV-2 rapid antigen test (RAT) compared with PCR. <b>Materials & methods:</b> Validation of RAT included 2295 subjects. Next matching of RAT with the PCR was checked in 13,852 subjects referred to PCR after being positive in RAT. <b>Results:</b> Sensitivity and specificity of RAT were 77.38 and 99.10%, respectively. A 74.60% of RAT positive results were confirmed with PCR. <b>Conclusion:</b> The test met WHO susceptibility criteria in a group of symptomatic subjects. In terms of specificity, it met requirements in all subjects. The concordance of RAT with PCR in real life was in line with our verification data.</p>","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/4b/fvl-2022-0045.PMC9514382.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40391734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sudden onset of decreased vision following Delta variant of SARS-CoV-2 infection: a case report","authors":"A. Ahmadi, N. Shafiei-Jandaghi, K. Sadeghi, M. Salehi, T. Mokhtari-azad, J. Yavarian","doi":"10.2217/fvl-2022-0006","DOIUrl":"https://doi.org/10.2217/fvl-2022-0006","url":null,"abstract":"We described a 52-year-old male patient with COVID-19 who had sudden decreased vision in his left eye in the second week of his illness. No occlusion thrombotic vein or hemorrhagic spots in retina have been identified in ophthalmoscopy procedures, clinical examination and optical coherence tomography. In one month his vision became normal without any treatment. We could not find the exact mechanisms of one-sided decreased vision in the COVID-19 patient, but this problem should be considered by physicians because of the importance of loss of vision.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47353285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case report of dengue shock syndrome complicated with multiorgan failure and hepatitis E virus superinfection","authors":"Kinza Waqar, Hashaam Akhtar, Muhammad Mujeeb Khan, M. Umar, B. Malik, M. Faheem","doi":"10.2217/fvl-2021-0239","DOIUrl":"https://doi.org/10.2217/fvl-2021-0239","url":null,"abstract":"Dengue fever is a vector borne viral disease. It is more prevalent in Southeast Asia. The main symptoms include myalgia, nausea, vomiting and rash, hence, subsequently lead to dengue hemorrhagic fever and dengue shock syndrome. In the current report, we are presenting a case of a 50-year-old female patient who was presented in hospital with the symptoms of fever, vomiting, abdominal pain, productive cough and sore throat. Her serology came positive for dengue NSP1, and she was shifted to intensive care unit because of her aggravating condition. On day 4, the hepatitis E virus infection also was detected and she died after developing hepatic shock and multiorgan failure. This report states the superinfection of hepatitis E and dengue virus and highlights the significance of its early detection for better clinical management.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2022-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45891620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}